RBD-4059
- Generic Name
- RBD-4059
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants with Stable Coronary Artery Disease
Phase 2
Recruiting
- Conditions
- Stable Coronary Artery Disease CAD
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Ribocure Pharmaceuticals AB
- Target Recruit Count
- 30
- Registration Number
- NCT06717074
- Locations
- 🇸🇪
Ribocure Clinic, Mölndal, Sweden
A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05653037
- Locations
- 🇦🇺
Q-Pharm Pty Limited, Brisbane, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath